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The aim of this study was to analyze the effects of microbial transglutaminase
(mTG) on the immunoreactivity of wheat and gluten-free cereals flours to the sera of
patients with celiac disease (CD) and non-celiac gluten sensitivity (NCGS). Both doughs
and sourdoughs, the latter prepared by a two-step fermentation with Lactobacillus
sanfranciscensis and Candida milleri, were studied. In order to evaluate the IgG-binding
capacity toward the proteins of the studied flours, total protein as well as protein
fractions enriched in albumins/globulins, prolamins and glutelins, were analyzed by
SDS-PAGE and enzyme-linked immunosorbent assay (ELISA). Results showed that
while mTG modified both gluten and gluten-free flour by increasing the amount of
cross-linked proteins, it did not affect the serum’s immune-recognition. In fact, no
significant differences were observed in the immunoreactivity of sera from CD and NCGS
patients toward wheat and gluten-free protein extracts after enzyme treatment, nor did
this biotechnological treatment affect the immunoreactivity of control samples or the
sera of healthy patients. These results suggest that mTG may be used as a tool to
create innovative gluten and gluten-free products with improved structural properties,
without increasing the immune-reactivity toward proteins present either in doughs or
in sourdoughs.
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INTRODUCTION
Celiac disease (CD) and non-celiac gluten sensitivity (NCGS) can be regarded as immune-mediated
systemic disorders elicited by gluten and related prolamins, among which deamidated gliadins are
the most immunogenic proteins (Volta et al., 2013). Epidemiological analysis on populations living
in western countries reported that 1% of the European population suffers from CD (Kurien et al.,
2016) while the prevalence of NCGS is still far from being established, ranging from 1% (primary
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care) to 6% (tertiary care) (Volta et al., 2014). Immune-
mediated mechanisms are triggered by gluten and evoke
intestinal mucosal damage resulting in villous atrophy in patients
with CD. This histopathological change is associated with
markedly reduced transmucosal absorption ending with nutrient
deficiency. Currently, the only therapeutic option for patients
with CD is a lifelong strict adherence to a gluten-free (GF) diet
(Dowd et al., 2014). Less information is available for NCGS,
although some authors have suggested an identical dietary
approach for NCGS patients. On the other hand, the quality of
baked products, in terms of viscosity, elasticity and cohesion,
is strictly dependent on gluten. Indeed, its capacity to create
protein aggregates and thus to confer structure and texture to
the dough, is a relevant feature for the quality of baked products
(Delcour et al., 2012). Producing GF baked goods with preserved
palatability and a good nutritional profile is themodern challenge
for food technology.
When added to dough, cross-linking enzymes such
as transglutaminases (TGs) can create protein networks
contributing to the structure of the dough; for this reason,
TGs are considered a promising tool for the food industry.
TGs are a widely distributed family of enzymes (E.C. 2.3.2.13)
(Del Duca and Serafini-Fracassini, 2005), belonging to the class
of transferases. Even if TGs from plant and microorganisms
lack sequence identity in respect to mammalian ones, they
share similar reactions and functions. In fact, either plant or
mTGs have conserved cysteine, histidine, and aspartate residues
that form the catalytic triad in structurally characterized TGs
(Makarova et al., 1999; Serafini-Fracassini et al., 2009).
TGs catalyze three post-translational protein modifications,
namely (i) transamidation, (ii) deamidation of endoglutamine
residues, and/or (iii) cross-linking between glutamine and lysine
residues (intra- or inter-chain), giving rise to protein aggregates
(Lorand and Graham, 2003). TGs are also involved in various
biological processes and clinical applications (Brunner et al.,
2002; Facchiano et al., 2006; Del Duca et al., 2014); further, they
are targets in therapeutic developments (Martins et al., 2014;
Strop, 2014).
Since the discovery of the first microbial TG (mTG) in
1989 (Ando et al., 1989), many efforts have been made in the
selection of mTG-producing strains and in the optimization
of the mTG production process (Motoki and Seguro, 1998)
with the aim of obtaining low-cost enzymes suitable for food
industry applications.
Nowadays, mTG is an important tool in the food industry
(Martins et al., 2014) as well as for research and biotechnological
applications (Camolezi Gaspar and Pedroso de Góes-Favoni,
2015). Improving firmness, viscosity, elasticity, and water-
binding capacity of food products in order to increase
organoleptic features, is of great interest in the food industry.
Thanks to their protein cross-linking reactions, mTGs have been
shown to be a suitable tool for food treatment (Kieliszek and
Misiewicz, 2014). Recently, mTG treatment was also shown
to improve the structure of GF dough by inducing protein
aggregation via protein cross-linking reactions (Scarnato et al.,
2016). Moreover, we reported the effects of the combination of
mTG and sourdough on the rheological properties, aroma, and
shelf-life of wheat bread (Scarnato et al., 2017) and the same
food technology has been applied on GF dough, which showed
an improved structure (Scarnato et al., 2016). Considering that
mTG is not only able to cross-link proteins, but also to catalyze
the deamidation of glutamine residue, the latter modification of
the mTG-treated products cannot be excluded a priori (Skovbjerg
et al., 2004; Gerrard and Sutton, 2005; Heil et al., 2016).
The aim of this research was to evaluate the capacity of mTG to
modify wheat and GF proteins by catalyzing protein cross-links
and to identify potential changes in the IgG immunoreactivity of
those proteins after biothecnological treatment.
MATERIALS AND METHODS
Flours and Doughs Preparation
Barilla S.p.A. (Parma, Italy) provided straight-grade wheat flour;
corn, rice and amaranth flours were purchased from local
markets. Flour doughs were prepared by mixing flour and
water (control dough); sourdough were prepared by adding L.
sanfranciscensis and C. milleri strain to the dough, as described
previously (Scarnato et al., 2016; Scarnato, 2017).
mTG Treatment of Flour Dough Proteins
Ajinomoto kindly provided the mTG, Activa WM (acTG) from
to Streptomyces mobaraensis, (specific activity: 81–135 U/g,
Ajinomoto Foods Europe S.A.S., France).
Treatment of doughs withmTGwere carried out bymixing 1U
of enzyme/100mg flour at 40◦C for 90min with constant stirring.
Then, treated doughs were stored at −20◦C in order to stop
mTG-activity or immediately processed for protein extraction.
Sera Used for Immunological Analysis of
Flour Proteins
A collection of sera from blood samples taken for diagnostic
purposes was identified in the serum bank of the Clinical
Immunology Laboratory (Department of Medical and Surgical
Sciences, St. Orsola-Malpighi Hospital of the University of
Bologna). The samples included for this study were selected
from sera labeled as “CD patients” (n = 14), “NCGS
patients” (n = 17), and “healthy control blood donors”
(HCBD) (n = 6). IgA anti-TG2 antibodies (TGA), IgG
anti-deamidated gliadin peptides antibodies (DGP) and anti-
endomysium antibodies (EmA) showed positivity along with
the presence of duodenal villous atrophy in patients diagnosed
with CD following a gluten-containing diet. NCGS patients
were diagnosed following the Salerno Experts Criteria (Catassi
et al., 2015). In detail, patients with NCGS are identified as
subjects with gluten-related symptoms that rapidly improved
after gluten withdrawal and in which CD and wheat allergy
have been ruled out. The symptom improvement was considered
indicative of NCGS if the score obtained from the modified
version of the gastrointestinal symptom rating scale (GSRS),
including extra-intestinal symptoms, decreased by at least 30%
from baseline after a gluten-free diet (GFD). In addition,
positivity for anti-native gliadin antibodies (AGA) of the
IgA and/or IgG class, although not specific, is regarded as
another tool supporting the NCGS diagnosis. Correct labeling
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of the selected sera was checked by retesting each sample
for TGA, EmA, DGP, AGA, and specific IgE for foods
and aeroallergens.
Since we used sera from anonymous blood samples taken for
diagnostic purposes, an approval from the St. Orsola-Malpighi
Ethics committee was deemed unnecessary. HCBD gave written
informed consent prior to blood sampling.
The collection of 36 human sera is listed in Table 1. Pooled
sera, containing individual serum from different groups (CD,
NCGS, and HCBD), were prepared by adding the same amount
of serum from each of the three types.
Serological Tests Performed With
Human Sera
Immunoglobulin A tissue transglutaminase antibodies (tTGA)
were measured using a commercially available ELISA kit (EuTG
IgA, Eurospital, Trieste, Italy), using recombinant human tissue
TG as antigen. A cut-off value of 16 arbitrary units (AU),
provided by the manufacturer, was adopted.
Immunoglobulin G deamidated gliadin peptide antibodies
(DGP) were assessed by ELISA using commercially available kits
(a-glia PEP, Eurospital, Trieste, Italy) and an entirely synthetic
peptide constructed in a conformational intact manner and
then selectively deamidated. According to the manufacturer’s
instructions, the cut-off value was set at 16 AU.
Immunoglobulin A endomysial antibodies (EmA) were
investigated by indirect immunofluorescence using human
umbilical cord cryostat sections (4mm), cut in our laboratory, as
substrate. Sera were tested at the initial dilution of 1:5 and, when
positive, titrated to the end point.
Immunoglobulin A and Immunoglobulin G anti-gliadin
antibodies (AGA)were determined by ELISA using commercially
available kits (a-gliatest SIgA and SIgG, Eurospital, Trieste, Italy)
and purified a-gliadin as antigen. The cut-off levels, as suggested
by the manufacturer, were fixed at 50 and 15AU for IgG and IgA
AGA, respectively.
Protein Extraction and Dialysis
Proteins from dough, treated with mTG, were extracted with
different buffers (1 g of flour/10mL of buffer) in order to
obtain total protein extracts (TE) and fractions enriched in
albumins and globulins (F1), prolamins (F2) and glutelins (F3).
All steps were carried out at 4◦C. To prepare total protein
extract, the dough was suspended in 100 mmol/L Tris HCl
pH 8.5 containing 20% glycerol and 1.7% β-mercaptoethanol.
The mixture was subjected to ultra-sonication for 30 s on
ice, and then incubated overnight with constant stirring. The
supernatant was collected after centrifugation at 5,000 g for
10min and then dialyzed against 0.1 mol/L acetic acid for
24 h using 6–8 kDa cut-off dialysis membranes. The protein-
enriched fractions were obtained using the same above-
described procedure but using different extraction buffers as
described by Rallabhandi et al. (2015), with minor modifications.
First, the dough was extracted twice with 0.5 mol/L NaCl
pH 7.5 for 1 h. The two supernatants, containing the F1-
enriched fraction, were pooled before dialyzing against distilled
water. The residual extraction pellet was washed with water
for 10min followed by centrifugation. Then, the pellet was
resuspended twice in 70% ethanol for 1 h. The extracts containing
prolamins (F2) were pooled and the solvent was removed
under vacuum. Finally, the glutelin fraction (F3) was extracted
by resuspending the residual pellet twice in 50% isopropanol,
1% acetic acid, 0.5% β-mercaptoethanol, followed by dialysis
against 0.1 mol/L acetic acid. All the protein extracts were
stored at −20◦C until further use. The protein content was
estimated using Bradford’s method with BSA as standards
(Bradford, 1976).
TABLE 1 | Clinical diagnosis and serum antibodies of patients.
ID Diagnosis EmA IgA tTG IgA DGP-IgG AGA IgA AGA IgG
1 CD pos++− 112.8 nd nd nd
2 CD POS++− 31.6 69.1 7.1 29.3
3 CD POS+++ 132.2 144.3 30.8 151.3
4 CD POS+−− 22.1 68.5 nd nd
5 CD nd 139.6 55.6 nd nd
6 CD POS+++ 116.9 39.6 3.9 42.7
7 CD nd 135.9 115.9 nd nd
8 CD nd 79.4 113.2 nd nd
9 CD POS+++ 152.8 101.6 28.5 138.9
10 CD nd 132.8 61.3 nd nd
11 CD POS+++ 151.9 106.4 19.1 104.2
12 CD POS+++ 150.9 96.4 49.1 139.6
13 CD POS++− 105.7 nd nd nd
14 CD nd 121.7 17.2 nd nd
15 NCGS NEG 4.8 5.1 4.6 40.1
16 NCGS NEG 4.0 9.5 8.8 114.9
17 NCGS NEG 5.4 36.0 12.7 65.1
18 NCGS NEG 5.6 19.7 8.5 34.1
19 NCGS NEG 4.5 7.9 6.0 47.8
20 NCGS NEG 5.3 3.4 8.8 44.4
21 NCGS NEG 5.0 26.0 5.9 85.8
22 NCGS NEG 5.2 5.3 8.0 41.6
23 NCGS NEG 5.8 7.6 4.6 51.7
24 NCGS NEG 4.5 4.5 7.3 50.7
25 NCGS NEG 4.5 7.0 7.0 87.0
26 NCGS NEG 5.1 7.6 6.3 40.7
27 NCGS NEG 2.4 4.1 5.1 54.1
28 NCGS NEG 5.7 10.0 8.3 43.0
29 NCGS NEG 5.9 22.8 8.0 119.0
30 NCGS NEG 4.2 3.3 6.6 54.1
31 NCGS NEG 5.2 3.4 7.8 88.5
32 HCBD NEG 1.0 nd nd nd
33 HCBD NEG 0.5 nd nd nd
34 HCBD NEG 1.5 nd nd nd
35 HCBD NEG 1.0 nd nd nd
36 HCBD NEG 0.8 nd nd nd
Coeliac disease (CD, patients 1–14), non-celiac gluten sensitivity (NCGS, patients 15–
31), and healthy control blood donors (HCBD, patients 32–36). EMA, anti-endomysial
antibodies; tTG, anti-tissue TG antibodies; DGP, anti-deamidated gliadin peptide
antibodies; AGA, anti-gliadin antibodies; IgA, immunoglobulin A; IgG, immunoglobulin G;
pos+−−, weak positive; pos+ + −,positive; pos+ + +, strong positive; neg, negative;
nd, not detectable.
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Protein Profile Analysis by SDS-PAGE
SDS-PAGE was performed according to the method of Laemmli
(1970). Samples were treated with reducing sample buffer for
5min at 95◦C and then run on 15% SDS-PAGE. Gels were stained
with Coomassie brilliant blue R-250 at room temperature and
then destained in 10% (v/v) acetic acid. Gels were scanned and
analyzed using the Bio-Rad Image Lab 4.0.1 Software.
Analysis of the IgG-Binding Capacity by
ELISA
First, 96-well Maxisorp plates (Nalgene, Rochester, NY) were
coated with 50 µL of the protein sample (5µg/mL) in 150
mmol/L phosphate buffer saline (PBS) overnight at 4◦C. The
plate was washed twice with PBS and subsequently nonspecific
binding sites were blocked with 200 µL/well of 1% BSA in
Tris buffer saline containing 0.05% Tween-20 (TBS-T), for
1 h at room temperature. Several serum dilutions (ranging
from 1:250 to 1:2,500) were tested in order to identify the
optimal number of antibodies for the development of the ELISA
analysis. IgG-binding capacity was tested by the addition of 50
µL/well of diluted patient and healthy control sera or pooled
sera, respectively, and incubated overnight at 4◦C. For each
protein sample, blank controls were tested using 0.5% BSA
in TBS-T instead of the diluted serum. After four washes, 50
µL/well alkaline phosphatase-conjugated polyclonal anti-human
IgG antibody (Thermo Fisher Scientific), diluted 1:1,000 in TBS-
T containing 0.5% BSA, was added. After 1 h of incubation
at 37◦C and another one at 4◦C, the plate was washed four
times with TBS-T and developed with 50 µL/well of substrate
solution, consisting of 10 mmol/L p-nitrophenyl phosphate
(PNPP) dissolved in alkaline substrate buffer pH 9.8 (9.7%
diethanolamine and 1mMMgCl2). The absorbance was recorded
using a microplate ELISA reader at 405 nm (ref. 490 nm). The
IgG-binding capacity of each protein sample was characterized
by corresponding OD values after background subtraction. The
ELISA protocol, coating conditions, reagent dilutions, buffers
and incubation times were tested in preliminary experiments.
Statistical Analysis
All data are reported as means ± SD. Data were analyzed
using GraphPad Prism by one-way ANOVA. Differences were
considered significant when p < 0.05 and very highly significant
when p < 0.001.
FIGURE 2 | SDS-PAGE of total protein extract and enriched protein fractions
(F1, F2, and F3) from rice control dough before (–) and after (+) mTG
treatment. Protein-enriched fractions: F1, albumins and globulins; F2,
prolamins; F3, glutelins. White asterisk along the lanes highlights bands that
change position along the lane after mTG treatment.
FIGURE 1 | SDS-PAGE of gluten (wheat) and GF flours (rice, corn, amaranth) total protein extracts from control dough before (–) and after (+) mTG treatment. Square
brackets show the region in the upper part of the lanes where mTG cross-linked proteins migrate.
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RESULTS
Cross-Linking Effect of mTG on
Protein Extracts
The mTG protein cross-linking products were evaluated in
control dough, after protein extraction and separation by
SDS-PAGE. As shown in Figure 1, after mTG treatment,
the protein profiles of gluten-containing dough and GF
dough in total protein extracts consisted of the disappearance
of some bands along the lanes and the accumulation of
protein aggregates. Some protein aggregates were unable
to enter the resolving gel, whereas a portion of crosslinked
protein does not even enter the stacking gel. These results
are the consequence of the cross-links between glutamine
and lysine residues of protein substrates catalyzed by
mTG (Scarnato et al., 2017).
The effects of enzyme treatment in the control dough
were evaluated also on protein enriched fractions, as shown
in Figure 2.
Fractions enriched in F1 and F3 were the main ones
involved in protein aggregation because of mTG catalysis of
cross-linked products. This has been revealed by the higher
accumulation of proteins in the wells and in the running-
stacking gel boundary regions in mTG-treated samples as
compared with the non-treated ones. Moreover, along the lanes,
some bands present in the non-treated sample disappeared
in the treated ones, possibly because of protein aggregation
to form high molecular weight products. This is particularly
evident for the 24 kDa band present in F1 fraction (not
treated with mTG) that disappeared when this fraction was
treated with mTG. Similar results were also observed either in
the other gluten-containing or the GF dough protein extracts
FIGURE 3 | IgG reactivity of sera determined using wheat protein extracts from control dough (W) and sourdough (Ws) treated with mTG (W(TG) and Ws(TG),
analyzed by ELISA. From the top: sera from CD patients (from P1 to P14); sera from NCGS patients (from P15 to P31); sera from HCBD (from P32 to P36).
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(total and enriched fractions) treated with mTG (data not
shown). The effect of mTG on sourdough protein extracts
from wheat and GF flours has been previously reported
(Scarnato et al., 2016, 2017).
mTG Effects on Flour Proteins
Immunoreactivity
In order to analyze the immunoreactivity of gluten and GF
proteins from control dough and sourdough, treated or not
with mTG, total protein extracts and F1-, F2-, and F3-enriched
fractions were analyzed by checking the IgG-binding capacity
of sera from gluten-sensitive patients and healthy blood donors.
Single serum IgG reactivity toward total wheat proteins extracted
from dough (W) and sourdough (Ws) is shown in Figure 3.
The IgG reactivity distribution of sera reflected the antibody
titers of each individual patient. Sera fromCDpatients andNCGS
P16 showed the highest immunoreactivity in terms of OD values,
whereas HCBD sera gave no or very low signals.
The graphs in Figure 3 represent the IgG reaction of each
individual serum used in the study. There are no significant
differences in reactivity within each individual serum toward
wheat proteins [all four types: total wheat extract (W), total
extract treated with mTG (W(TG)), sourdough (Ws), sourdough
+mTG (Ws(TG))].
From the data presented in Figure 3, it is possible to observe
that the reactivity of the 36 patients among each other is
extremely variable even inside categories of CD, NCGS patients.
There is generally a higher IgG reactivity in the CD group,
medium reactivity for the NCGS and nearly no reactivity in
FIGURE 4 | IgG-binding capacity, expressed as OD value of gluten-containing dough and GF flour control dough before (-) N and after (+) • mTG treatment using
pooled CD patient’ sera (P1–P14). Data are presented as mean values of 7 replicates with significance level: ns= not significant, *p < 0.05, **p < 0.01, and ***p <
0.001. W, wheat; R, rice; C, corn; A, amaranth.
FIGURE 5 | IgG-binding capacity of rice total protein extracts using a pool of sera from CD patients (P1–P14). The protein from rice dough and sourdough were
treated with mTG. Data are reported as absorbance at 405 nm of sera diluted 1:250. Data are presented as mean values with significant level: *p < 0.05, **p < 0.01,
and ***p < 0.001.
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the healthy controls. This figure is associated with the Table 1,
which describes the clinical diagnosis and serum antibodies level
of patients.
The IgG-binding capacity of total protein extracts, before (–)
and after (+) mTG treatment, was analyzed using CD patients’
pooled sera in order to have a representative trend and to
eliminate the variability factor among individuals; data of wheat
and GF flours control dough are reported in Figure 4.
Enzymatic treatment did not change the immunoreactivity of
total protein extracts both in corn and in amaranth, while in
wheat (p < 0.001) and rice doughs (p < 0.01), mTG treatment
significantly decreased the IgG-binding capacity. The OD values
represent the level of IgG reactivity to any of the wheat, rice,
corn and amaranth proteins present in dough extracts. A higher
value indicates that more IgG antibodies against surface-exposed
proteins of the flour sources are present in the sera.
The combined effect of mTG and sourdough on GF dough
proteins was also analyzed using CD, NCGS, and HCBD pools
of sera. Both biotechnological treatments (mTG and sourdough)
influenced the immuno-recognition of the sera. As representative
data, the total protein extracts from rice doughs, analyzed with
the CD patients pool of sera, are shown in Figure 5.
mTG treatment significantly reduced (p < 0.01) the
specific antibody binding capacity of the protein derived
from rice dough. Sourdough fermentation caused a
reduction (p < 0.05) of the immunoreaction. The statistical
analysis did not show any significant differences when
the Rs (mTG) sample was compared to the Rs and to R
(mTG) samples. In fact, both treatments (sourdough and
mTG) resulted in significant antigenicity reduction and
the combined treatment did not lead to more decreased
antigenicity (Figure 5).
The IgG-binding capacity of total protein extracts from
gluten-containing dough and GF dough was measured using
pooled sera from NCGS patients (P15–P31) (Figure 6).
This analysis, performed both with wheat and GF doughs,
supports the data obtained with CD sera; dough protein
immunoreactivity did not increase after mTG treatment. On the
contrary, when tested with NCGS sera, mTG treatment decreased
immune recognition in doughs of wheat, corn and amaranth
(Figure 6). To further evaluate protein IgG reactivity, control
dough proteins were extracted by a sequential method using
specific buffer solutions. IgG-binding capacity toward F1-, F2-,
and F3-enriched fractions, treated or not with mTG, was tested in
order to better identify which class of protein showed the highest
signal when treated with sera from CD and NCGS patients.
Results indicate a different immunoreactivity of wheat
dough compared to GF dough samples. In fact, wheat protein
extracts, and in particular the F3 fraction, showed the highest
immunoreactivity, both when tested with CD and NCGS
sera. In all the GF samples, immunoreactivity of F2 and F3
fractions was very low and in amaranth F3 did not reach the
detection limit of the method. In general, F1 of the GF samples
was the only fraction showing considerable immunoreactivity
(Figure 7A). In all samples, the CD patients’ sera showed a higher
immunoreactivity when compared to NCGS patients (Figure 7).
Moreover, mTG treatment did not affect the IgG reactivity profile
in any of the tested flour doughs.
DISCUSSION
The lack of structure in bread dough is a difficult challenge
while working with GF cereal products. In fact, GF products
FIGURE 6 | IgG-binding capacity, expressed as OD value of gluten and GF flours before (–) N and after (+) • mTG treatment, determined by ELISA assay using
pooled sera from NCGS patients (P15–P31). Data are presented as mean values of 7 replicates with significance level: ns = not significant, *p < 0.05, **p < 0.01, and
***p < 0.001. w, wheat; r, rice; c, corn; a, amaranth.
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available on the market are often of low nutritional quality
and poor taste. Without gluten, wide ranges of ingredients (i.e.,
hydrocolloids) are needed to obtain products with organoleptic
features appreciated by consumers (Moreira et al., 2013). mTG is
proposed as a biotechnological agent to improve the functional
properties of structurally poor flour proteins as a processing
aid, as it can induce structural protein modifications improving
the features of the final product (Camolezi Gaspar and Pedroso
de Góes-Favoni, 2015). In our earlier work, GF cereal doughs
and sourdoughs made by using Lactobacillus sanfrancisciensis
and Candida milleri were subjected to enzymatic treatment by
supplyingmTG from Streptomyces mobaraensis in order to obtain
doughs with an improved texture (Scarnato et al., 2016, 2017).
However, the effect of mTG on the immunoreactivity of these
doughs was not completely clarified. Therefore, this study was
undertaken in order to verify if the mTG reaction affected the
immunoreactivity of the treated doughs. In fact, concerns were
raised about the use of mTG for flour protein modification
as human tissue TG is involved in gliadin deamidation, a key
reaction in the etiology of CD. Deamidated gliadins are known
to increase immunoreactivity to gluten peptides in CD patients
(Sollid, 2000). Moreover, Gerrard and Sutton (2005) suggested
that further research was needed to assess this possibility and
recommended that TG should not be used in bakery products
until this issue is resolved.
Previous studies showed that mTG in combination with
sourdough exhibited a positive and synergistic effect by
which the excessive hardness and chewiness caused by mTG
were counteracted by the sourdough. On the other hand,
the protein-aggregating effect of mTG compensated for the
FIGURE 7 | IgG-binding capacity, expressed as OD value of gluten and GF flours dough using pooled sera from CD and NCGS patients, before (A) and after (B) mTG
treatment. Three protein-enriched fractions were analyzed, F1 (albumin and globulins), F2 (prolamins) and F3 (glutelins). Data are presented as mean values ± SD. a,
wheat; b, rice; c, corn; d, amaranth.
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proteolytic action of sourdough on protein substrates, which
reduces the viscoelastic properties of bread. Data showed
that the gluten fraction was the main fraction involved in
these cross-links, but in GF flours, mTG was able to exert
its action also on the F1 (Albumin and Globulin)-enriched
fraction. When mTG activity was checked by microplate
assay (while incorporating biotin-cadaverine (BC) on protein
substrate immobilized on a microplate), F2 was the main
fraction involved in the incorporation of BC, followed
by F1-enriched fraction in lentil and amaranth and by
F3 (Glutelin)-enriched fraction in rice and corn. The use
of sourdough combined with mTG showed a synergistic
beneficial effect on bread characteristics, with improved
bread rheological features, aroma profile and shelf-life of
the baked product. The excessive hardness and chewiness
of bread caused by increasing concentrations of mTG were
counteracted by the addition of a proper amount of sourdough.
On the other hand, the degradative action of sourdough on
protein substrates, which reduced the viscoelastic properties of
bread, was compensated by the protein-aggregating effect of
mTG (Scarnato et al., 2016, 2017).
The aim of the present research was to investigate if
the protein modification catalyzed by mTG could affect the
immunological features of dough proteins, previously studied
for their rheological and organoleptic properties. Data showed
that mTG treatment in both gluten and GF flours did not cause
a significant increase of IgG-binding capacity. These results
provide a perspective in research on GF products, suggesting the
possible use of mTG as a biotechnological agent able to create
innovative products; its action does not alter the IgG-binding
epitopes on substrate proteins.
Under the experimental conditions of our study, mTG protein
cross-linking did not affect antibody-binding capacity, thus
corroborating results from previous studies. For example, no
immunological changes of gliadin extract from pasta dough
treated with mTG using the sera of CD patients was observed
(Ruh et al., 2014). Interestingly, other data showed that cross-
linked gluten flour had a lower immunoreactivity in a rabbit
model system, suggesting that the lower deamidation rate of
mTG relative to mammalian TGs, together with the cross-
linking of gluten peptides, might potentially reduce this risk
(Leszczynska et al., 2006). Moreover, transamidation of wheat
flour with a food-grade enzyme and an appropriate amine donor
can be used to block T cell-mediated gliadin activity and to
prevent cereal toxicity (Gianfrani et al., 2007). Immunoblotting
using monoclonal antibodies specific to unmodified and/or
deamidated gliadin showed no differences between control bread
and bread obtained after treatment of the dough with mTG.
According to the authors, the concentrations of mTG used in
wheat bread preparation do not lead to detectable amounts of
deamidated gliadin (Heil et al., 2017).
On the other hand, Berti et al. (2007) demonstrated that mTG-
deamidated gliadins increase the IgA antibody reactivity of CD
patients with respect to control gliadins (Berti et al., 2007). Others
reported an increased immunoreactivity of a CD serum pool to
gliadin from bread treated with mTG (Gerrard and Sutton, 2005;
Cabrera-Chávez et al., 2008). Recently, Torsten and Aaron (2018)
hypothesized that mTG used in food preparation could favor
celiac disease initiation and progress. As TGs are also present in
plants (Del Duca et al., 2000, 2010; Skovbjerg et al., 2002; Serafini-
Fracassini et al., 2009), plant-derived food could be another
source for TGs that might reach the reach intestinal tract where
these TGs (food derived ones and mTG from microbiota) could
play a pathogenic role. This last hypothesis is suggestive but, to
our knowledge, not supported by solid experimental evidence.
To settle the question, it has been suggested to test new
products by applying the immunoreactivity assay using the sera
of CD patients (Cabrera-Chávez et al., 2008). This simple and
reliable test could be an easy way to evaluate ingredients and
procedures to obtain new GF products and to identify potentially
unsafe products. Moreover, further investigations using mouse
models could be useful to assess the immunogenicity of mTG
doughs and sourdoughs.
In summary, by following the experimental procedure
reported in this paper, treatment of gluten and GF flour doughs
with mTG leads to an increase in cross-links but does not lead
to significant changes in the IgG binding reactivity of the protein
extracts with sera from either CD or NCGS patients’ sera.
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